Clinical trial · Observational
Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies
Development of a Method for Assessing the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies Using Flow Cytometry
NCT05654766CI-TRIAL-00062737unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to develop a highly sensitive method for assessing the functional activity of platelets for use in the differential diagnosis of thrombocytopenia and platelet defects.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Leukemia | Acute Leukemia | ONTOLOGY_EXACT | 0.90 |
| Hemorrhagic Disorders | — | UNRESOLVED | — |
| Immune Thrombocytopenia | — | UNRESOLVED | — |
| Thrombocytopathy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Flow cytometry | Diagnostic Test | — | UNRESOLVED |
| Platelet aggregation and plasma coagulation | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Control group
- description
- Group of healthy adult and pediatric participants, whose blood platelets will be used to evaluate normal ranges of parameters in the flow cytometry PFT.
- interventionNames
- Diagnostic Test: Flow cytometry
- Diagnostic Test: Platelet aggregation and plasma coagulation
- label
- Hemorrhagic syndrome and Acute Leukemia
- description
- Group of pediatric participants with any manifestations of hemorrhagic syndrome and/or acute leukemia
- interventionNames
- Diagnostic Test: Flow cytometry
- Diagnostic Test: Platelet aggregation and plasma coagulation
Primary outcomes (12)
- measure
- Expression of CD42b by platelets
- timeFrame
- baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 17 Years
Show eligibility criteria text
Inclusion Criteria: * Pediatric participants with hemorrhagic syndrome (hemorrhagic rash, bruising, bleeding, increased bleeding of the skin and mucous membranes, spontaneous hemorrhages in soft tissues and joints) * Pediatric participants with acute leukemia * Parameters of the plasma level of blood coagulation correspond to the age normal levels Exclusion Criteria: * Anticoagulation drug therapy * Antiaggregation drug therapy * Biologically active additives
References
Publications (0)
Data not yet available
No reference posted for this study.